Estija - estų - Ravimiamet

stada arzneimittel ag - dabigatraaneteksilaat - kõvakapsel - 150mg 10tk; 150mg 180tk

Estija - estų - Ravimiamet

stada arzneimittel ag - tadalafiil - õhukese polümeerikattega tablett - 10mg 20tk; 10mg 4tk; 10mg 16tk; 10mg 24tk; 10mg 28tk; 10mg 30tk; 10mg 12tk; 10mg 60tk

Estija - estų - Ravimiamet

stada arzneimittel ag - dabigatraaneteksilaat - kõvakapsel - 75mg 30tk; 75mg 10tk

Europos Sąjunga - estų - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatiid - osteoporoos - kaltsiumi homöostaas - movymia on näidustatud täiskasvanutel. osteoporoosi ravi postmenopausis naistel ja meestel, kellel on suurem luumurdude risk. postmenopausaalsetel naistel on selgelt ja selgroogsete luumurdude, kuid mitte puusaluumurdude esinemissageduse märkimisväärne vähenemine. ravi osteoporoosi seostatakse pidevat süsteemset glükokortikoidi ravi naiste ja meeste suurenenud risk luumurdude.

Estija - estų - Ravimiamet

sandoz pharmaceuticals d.d. - klopidogreel - õhukese polümeerikattega tablett - 75mg 90tk; 75mg 500tk; 75mg 50tk; 75mg 60tk; 75mg 56tk; 75mg 100tk; 75mg 30tk; 75mg 84tk; 75mg 14tk; 75mg 98tk

Estija - estų - Ravimiamet

auxilia pharma oÜ - klopidogreel - õhukese polümeerikattega tablett - 75mg 90tk; 75mg 100tk; 75mg 14tk; 75mg 84tk; 75mg 50tk; 75mg 28tk

Estija - estų - Ravimiamet

zentiva k.s. - klopidogreel - õhukese polümeerikattega tablett - 75mg 14tk; 75mg 90tk; 75mg 30tk

Estija - estų - Ravimiamet

vale pharmaceuticals limited - paratsetamool+ibuprofeen - infusioonilahus - 10mg+3mg 1ml 100ml 10tk

Europos Sąjunga - estų - EMA (European Medicines Agency)

stada arzneimittel ag - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Europos Sąjunga - estų - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, soole põletikuvastased / antiinfective ained - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.